C57BL/6NCya-Cldn18em1/Cya
Common Name
Cldn18-KO
Product ID
S-KO-10853
Backgroud
C57BL/6NCya
Strain ID
KOCMP-56492-Cldn18-B6N-VA
Status
When using this mouse strain in a publication, please cite “Cldn18-KO Mouse (Catalog S-KO-10853) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
Basic Information
Strain Name
Cldn18-KO
Strain ID
KOCMP-56492-Cldn18-B6N-VA
Gene Name
Product ID
S-KO-10853
Gene Alias
--
Background
C57BL/6NCya
NCBI ID
Modification
Conventional knockout
Chromosome
Chr 9
Phenotype
Datasheet
Application
--
Strain Description
Ensembl Number
ENSMUST00000035048
NCBI RefSeq
NM_019815
Target Region
Exon 2~4
Size of Effective Region
~2.9 kb
Overview of Gene Research
Claudin-18 (Cldn18), specifically the isoform Cldn18.2, is a transmembrane protein and a major component of tight junctions, playing a crucial role in maintaining barrier function [4]. It is expressed in normal gastric cells and is retained in malignant gastric or gastroesophageal junction (G/GEJ) adenocarcinoma cells [1].
In recent clinical trials, monoclonal antibodies targeting Cldn18.2 have shown promise. For example, zolbetuximab plus chemotherapy regimens (such as CAPOX or mFOLFOX6) significantly improved progression-free survival and overall survival in patients with Cldn18.2-positive, HER2-negative, locally advanced unresectable or metastatic G/GEJ adenocarcinoma [1,2]. Additionally, Cldn18.2-positive gastric cancer (GC) has distinct immune-microenvironmental characteristics, with differences in the proportion of certain immune cells compared to Cldn18.2-negative tumors [3].
In conclusion, Cldn18.2 is a potential therapeutic target, especially in gastric and gastroesophageal junction adenocarcinomas. The development of monoclonal antibodies against Cldn18.2 offers new treatment options for patients with these malignancies. Understanding the role of Cldn18.2 in the tumor immune microenvironment may also help optimize targeted therapies for these cancers [1,2,3].
References:
1. Shah, Manish A, Shitara, Kohei, Ajani, Jaffer A, Arozullah, Ahsan, Xu, Rui-Hua. 2023. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. In Nature medicine, 29, 2133-2141. doi:10.1038/s41591-023-02465-7. https://pubmed.ncbi.nlm.nih.gov/37524953/
2. Shitara, Kohei, Lordick, Florian, Bang, Yung-Jue, Oh, Mok, Ajani, Jaffer A. 2023. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. In Lancet (London, England), 401, 1655-1668. doi:10.1016/S0140-6736(23)00620-7. https://pubmed.ncbi.nlm.nih.gov/37068504/
3. Jia, Keren, Chen, Yang, Sun, Yu, Zhang, Cheng, Shen, Lin. 2022. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer. In BMC medicine, 20, 223. doi:10.1186/s12916-022-02421-1. https://pubmed.ncbi.nlm.nih.gov/35811317/
4. Chen, Jinxia, Xu, Zhiyuan, Hu, Can, Yuan, Li, Cheng, Xiangdong. 2023. Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications. In Frontiers in oncology, 13, 1132319. doi:10.3389/fonc.2023.1132319. https://pubmed.ncbi.nlm.nih.gov/36969060/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.